GET DAILY SIGNALSAlnylam Pharmaceuticals (ALNY): Can the Shares Climb Back Toward the $300 Target?
Key Takeaways
- The central $300 stock price target is the arithmetic mean of 17 recent, verifiable analyst price targets, which average roughly $295 and are rounded to a clean $300 figure.
- The latest verified closing price is approximately $155.94, meaning the stock would need to rise roughly 92% to reach the target.
- Individual analyst targets are unusually wide, spanning from about $199 (Bernstein) to roughly $455, reflecting sharp disagreement about the durability of Amvuttra's growth.
- The strongest supports are Alnylam's RNAi leadership, a large under-treated patient population, and a deep pipeline across cardiovascular, central nervous system, and metabolic diseases.
- The biggest risks are slowing Amvuttra demand, new insurer restrictions, 340B drug-pricing headwinds, and clinical uncertainty around the TRITON-CM trial.
- You can explore the latest Major News, Today's Price Move, Forecast, and Earnings on dedicated pages for deeper detail.
- Explore Trending AI Robots to see how AI-driven trading systems are monitoring stocks like ALNY.
Analyst Price Targets and Consensus View
Following Alnylam Pharmaceuticals' Q3 2026 report, Wall Street reset its expectations sharply lower. In this review, 17 individual targets were averaged, producing a mean near $295 and a rounded central target of $300. The spread is very wide — from Bernstein's $199 (downgrade to Market Perform) up to roughly $455 on the high end — which signals that analysts genuinely disagree about the stock's direction rather than clustering around a consensus.
Several firms maintained constructive ratings while trimming targets: Goldman Sachs cut to $320 (Buy), UBS to $329 (Buy), Citi to $320 (Buy), and Bank of America to $287 (Buy). Others turned more cautious, with Raymond James downgraded to Outperform ($315), Stifel to Hold ($225), and Truist to Hold ($225). Morgan Stanley ($240) and Wells Fargo ($220) sit near the low end, while Piper Sandler ($410) and Barclays ($380) remain among the more optimistic. The central figure is an average analyst price target, not a published official consensus, and it should be read as a reference point rather than a guarantee. I also checked this using Tickeron’s AI Screener to see how ALNY compares to others in the industry.
Current Market Position and Path Toward the Target
At a verified price near $155.94, the required move to $300 is approximately 92% — a very large advance. The shares have fallen roughly 64% over the trailing 52 weeks and about 56% year to date, leaving the stock near its 52-week low of $154.30 against a high of $479.79. Reaching the target would require a sustained re-rating, not a modest bounce.
The path depends on evidence that Amvuttra's demand trajectory stabilizes and re-accelerates. Management guided 2026 TTR franchise revenue toward the lower end of its $4.2–$4.5 billion range and acknowledged slower-than-hoped patient conversion. Analysts flag limited near-term visibility, with key Phase 2 and Phase 1 pipeline data now expected in February 2027 and 2027 guidance deferred to that same window.
What Could Support a Move Toward the Target
Alnylam Pharmaceuticals remains the clear leader in RNAi therapeutics with a validated commercial engine. Amvuttra generated roughly $1.13 billion in Q3 revenue, and the company estimates about 80% of eligible ATTR-CM patients are still untreated, implying a substantial addressable market. Revenue growth is strong (roughly 46–56% in recent periods), the balance sheet is solid, and the pipeline spans hypertension (zilebesiran), Huntington's disease, bleeding disorders, and obesity — each a potential long-term catalyst that could justify a higher valuation.
What Could Prevent the Target From Being Reached
The near-term risks are concrete. UnitedHealthcare's new coverage restrictions, effective October 1, 2026, limit Amvuttra access for an estimated 10% of patients. The 340B drug-pricing program introduces additional pressure from January 1, 2027. Slowing sequential U.S. demand growth, longer patient-conversion times, and uncertainty over the design and event rates of the TRITON-CM Phase 3 trial for nucresiran have all driven downgrades. If Amvuttra's trajectory does not improve, the low end of the analyst range could remain in play.
Technical Levels and Market Structure
The stock is trading just above its 52-week low of $154.30, which now serves as the key support level. A break below it would open fresh downside. On the upside, the 200-day moving average near $280 and the psychological $200 and $300 levels represent notable resistance zones, with the former 52-week high of $479.79 marking the far upper boundary of the prior range.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms differ. Investors should watch Amvuttra prescription and demand trends, any updates on insurer access and 340B impact, the February 2027 pipeline data readouts and 2027 guidance, and further analyst revisions. Fourth-quarter results and management commentary on new-patient starts will be especially important for gauging whether the demand slowdown is temporary.
AI Daily Buy/Sell Signals
I have found Tickeron's AI Daily Buy/Sell Signals helpful for monitoring stocks like ALNY. These tools use artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening allows. For investors following volatile biotech names, automated signal tracking can complement fundamental research and help flag momentum changes as they develop.
Final Assessment
Reaching $300 would require Alnylam Pharmaceuticals to recover roughly 92% from its current price — a very large move that hinges on restoring confidence in Amvuttra's growth rather than a simple valuation snapback. The bull case rests on RNAi leadership, a vast untreated patient base, and a promising pipeline, while the bear case centers on demand deceleration, insurer and 340B headwinds, and clinical-trial uncertainty. The wide analyst range — from $199 to roughly $455 — underscores how much depends on upcoming data and demand evidence. The central $300 figure is a useful reference point, not a forecast, and investors should weigh both the substantial upside and the very real execution risks before drawing conclusions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ALNY's Stochastic Oscillator is remaining in oversold zone for 5 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +1.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALNY advanced for three days, in 216 of 297 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
ALNY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALNY as a result. In 58 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
The Moving Average Convergence Divergence Histogram (MACD) for ALNY turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 32 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 70%.
The 10-day moving average for ALNY crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALNY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
The Aroon Indicator for ALNY entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. ALNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.409) is normal, around the industry mean (3.498). P/E Ratio (26.566) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.330) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (6.911) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutics based on RNA interference
Industry Biotechnology
Advertisement